hotspot -WSS

hotspot

author：knowledge 2025-09-28 01:39:26 - browse：84922

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Startling documents reveal new facets of Sacklers' opioid empire

WSS

Insmed lung disease drug hits target in key Phase 3 trial

There's no autism epidemic. It's an autism diagnosis epidemic

Decaf coffee targeted by food safety group under obscure FDA rule

Report: NIH

Health insurers say they are turning to AI to cut costs, improve care

Biohaven protein

knowledge

hotspot

leisure time

Medicare details structure of new drug price negotiation program

Primary care physicians play key roles in Alzheimer's management

New air purifier tech could be key to improving indoor air quality

Food as medicine: Medically tailored meals may get standardized

Bright Health sells Medicare Advantage business to Molina

Average age of first period drops to 11.9 years, study shows

Peter Hotez and the public health issue of online harassment

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

New air purifier tech could be key to improving indoor air quality

Steward Health Care has deal to sell doctor network to UnitedHealth

explore

Average age of first period drops to 11.9 years, study shows

Addiction doctors spar with methadone clinics over legislation

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Report: NIH

Abortion pill case raises question: who can sue the FDA?

Readout Newsletter: Merck, Vertex, and Viking updates

Wikipedia

explore

Wikipedia

leisure time